TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28169875

Group type: EXPERIMENTAL
Intervention: Vitamin A deficiency
Number of subjects: 1571

Group type: EXPERIMENTAL
Intervention: Vitamin D deficiency
Number of subjects: 1571
Study: 26359814

Group type: EXPERIMENTAL
Intervention: IR1W (830 nm, 100 mW, 5 J, 176 J/cm2, 50 s, 10 sessions)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: IR3W (830 nm, 100 mW, 5 J, 176 J/cm2, 50 s, 9 sessions)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Red laser (685 nm, 35 mW, 2 J, 72 J/cm2, 58 s, 9 sessions)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: All groups (including CG)
Number of subjects: 78
Study: 25001961

Group type: EXPERIMENTAL
Intervention: Oxytocin (40 IU intranasally)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline placebo (control)
Number of subjects: 60
Study: 21773714

Group type: EXPERIMENTAL
Intervention: Polyherb (Tinospora cordifolia and Zingiber officinale based)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Monoherb (Semecarpus anacardium)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Hydroxychloroquine sulfate (HCQS)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: HCQS and Polyherb
Number of subjects: 121
Study: 19331705

Group type: EXPERIMENTAL
Intervention: Dietary intervention combining nutrition information with increased availability of vegetables, fruits, and wholegrain bread
Number of subjects: 481

Group type: EXPERIMENTAL
Intervention: Increased intake of folate from wholegrain bread
Number of subjects: 481
Study: 17768058

Group type: EXPERIMENTAL
Intervention: 7.2g alpha-ketoglutaric acid and 720 mg 5-hydroxymethylfurfural/day (SANOPAL) from days 1 to 10
Number of subjects: 32
Study: 15229713

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation for everyone in Scandinavia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Iron and folate supplements for women of fertile age
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multivitamin and mineral pill for people in risk groups
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High doses of vitamins and minerals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Healthy diet
Number of subjects: 0
Study: 12109935

Group type: EXPERIMENTAL
Intervention: Sustained-release bupropion (bupropion SR) 150mg twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sustained-release bupropion (bupropion SR) 300mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sustained-release bupropion (bupropion SR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nicotine transdermal patch
Number of subjects: 0
Study: 9817266

Group type: EXPERIMENTAL
Intervention: CA10 (10 cycles of doxorubicin)
Number of subjects: 299

Group type: COMPARATOR
Intervention: CA5 (5 cycles of doxorubicin)
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: CA10 with moderate/high dose-volume cardiac RT
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: CA5 with locoregional RT
Number of subjects: 299
Study: 8176012

Group type: EXPERIMENTAL
Intervention: Sunscreens containing 2% or 5% oxybenzone
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo (0% oxybenzone)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Sunscreens containing 7% octyl dimethyl para‐aminobenzoic acid
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: All tested formulations
Number of subjects: 5
Study: 3582314

Group type: EXPERIMENTAL
Intervention: Exposure to a standard mixture of 22 different organic gases and vapors
Number of subjects: 62
Study: 28834390

Group type: EXPERIMENTAL
Intervention: Treat-to-target (TTT) strategy implementation
Number of subjects: 641
Study: 27938358

Group type: EXPERIMENTAL
Intervention: pMDI BDP/FF 200/6 (two actuations bid)
Number of subjects: 376

Group type: COMPARATOR
Intervention: BDP 100 μg (four actuations bid)
Number of subjects: 376
Study: 26646404

Group type: EXPERIMENTAL
Intervention: Inhaled isoflurane
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intravenous midazolam and/or propofol
Number of subjects: 60
Study: 23455860

Group type: EXPERIMENTAL
Intervention: Criteria-based reminder to remove the catheter
Number of subjects: 278

Group type: COMPARATOR
Intervention: No reminder
Number of subjects: 278
Study: 20565044

Group type: EXPERIMENTAL
Intervention: Saint John's Wort Extract (antidepressant treatment)
Number of subjects: 30
Study: 18223608

Group type: EXPERIMENTAL
Intervention: High Oleic Acid (HI OA) diet (PA = 1.7%, OA = 31.4%)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: High Palmitic Acid (HI PA) diet (PA = 16.8%, OA = 16.4%)
Number of subjects: 43
Study: 19291124

Group type: EXPERIMENTAL
Intervention: Be Proud! Be Responsible! intervention
Number of subjects: 1357

Group type: COMPARATOR
Intervention: General health promotion program (control)
Number of subjects: 1357
Study: 15752403

Group type: EXPERIMENTAL
Intervention: Injection of thermal indicator into the right atrium
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Injection of thermal indicator into the right ventricle
Number of subjects: 50
Study: 11560559

Group type: EXPERIMENTAL
Intervention: 20 mg intravesical MMC plus local hyperthermia (Group 1)
Number of subjects: 51

Group type: COMPARATOR
Intervention: 20 mg MMC alone (Group 2)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 40 mg intravesical MMC plus local hyperthermia (Group 3)
Number of subjects: 51

Group type: COMPARATOR
Intervention: 40 mg MMC alone (Group 4)
Number of subjects: 51
Study: 9623316

Group type: EXPERIMENTAL
Intervention: Cisapride, 3 x 5 mg in a suspension one day before surgery and 30 mg 3 and 8 hours after surgery, followed by 2 x 30 mg in suppositories until oral ingestion is possible
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7910488

Group type: EXPERIMENTAL
Intervention: Antacid with cimetidine
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Antacid with ranitidine
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Antacid with nizatidine
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Antacid with famotidine
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Antacid with all agents tested
Number of subjects: 21
Study: 3294618

Group type: EXPERIMENTAL
Intervention: Digitoxin
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 31664624

Group type: EXPERIMENTAL
Intervention: Support Vector Machine (SVM)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Random Forest (RF)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Partial Least Squares Discriminant Analysis (PLS-DA)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Logistic Regression (LR)
Number of subjects: 54
Study: 30518583

Group type: EXPERIMENTAL
Intervention: Cumulative network meta-analysis (NMA) of drug treatments for postmenopausal osteoporosis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Practice guidelines recommendations
Number of subjects: 0
Study: 26643027

Group type: EXPERIMENTAL
Intervention: Religious support expression
Number of subjects: 0

Group type: COMPARATOR
Intervention: General emotional support messages
Number of subjects: 0
Study: 25188297

Group type: EXPERIMENTAL
Intervention: Tiotropium 2.5 µg
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: Tiotropium 5 µg
Number of subjects: 510

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 510
Study: 22115944

Group type: EXPERIMENTAL
Intervention: Spinosad and milbemycin oxime combination (30-45 mg/kg spinosad; 0.5-0.75 mg/kg MO)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 20
Study: 19900070

Group type: EXPERIMENTAL
Intervention: Chondroitin 4 and 6 sulphate (CS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 0
Study: 17448179

Group type: EXPERIMENTAL
Intervention: Rizatriptan 10 mg
Number of subjects: 707

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 707
Study: 15451915

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Cross-sectional study
Number of subjects: 77
Study: 11215606

Group type: EXPERIMENTAL
Intervention: Storage in saline-containing preservatives
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 44

Group type: COMPARATOR
Intervention: Cefazolin and gentamicin
Number of subjects: 44
Study: 10193296

Group type: EXPERIMENTAL
Intervention: Mouthpiece alone
Number of subjects: 20

Group type: COMPARATOR
Intervention: Face mask
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Mouthpiece with noseclip
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Mouthpiece
Number of subjects: 20
Study: 7532930

Group type: EXPERIMENTAL
Intervention: Balloon occluded arterial infusion (BOAI) treatment with cisplatin (100 mg/m2), aclacinomycin (30 mg/m2) and bleomycin (20 mg/m2)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Intravenous (i.v.) administration of the same drugs (cisplatin, aclacinomycin, bleomycin)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Balloon occluded arterial infusion (BOAI) treatment
Number of subjects: 19
Study: 3284402

Group type: EXPERIMENTAL
Intervention: EMLA 5% cream
Number of subjects: 111

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study: 30567567

Group type: EXPERIMENTAL
Intervention: Post-discharge malaria chemoprevention (PMC) with dihydroartemesinin-piperaquine (DHP)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Home visit reminders by health surveillance assistants (HSAs)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Factors influencing adherence to home visits
Number of subjects: 39
Study: 27428338

Group type: EXPERIMENTAL
Intervention: Transfusions and erythropoietin (E)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Transfusions (T)
Number of subjects: 80
Study: 25336121

Group type: EXPERIMENTAL
Intervention: Multicomponent dyadic intervention (exercise and support)
Number of subjects: 0
Study: 24360107

Group type: EXPERIMENTAL
Intervention: 40 mg parecoxib infusion 30 min preoperative and at 12, 24, 36, 48 h post-operation
Number of subjects: 80

Group type: COMPARATOR
Intervention: 2 ml normal saline infusion (placebo)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 40 mg parecoxib infusion
Number of subjects: 80
Study: 20689921

Group type: EXPERIMENTAL
Intervention: NIV algorithm (NIV+)
Number of subjects: 65

Group type: COMPARATOR
Intervention: No NIV algorithm (NIV0)
Number of subjects: 65
Study: 18422481

Group type: EXPERIMENTAL
Intervention: Tolterodine (immediate or extended-release formulations)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other antimuscarinic agents
Number of subjects: 0
Study: 16810076

Group type: EXPERIMENTAL
Intervention: Fenofibrate (200 mg)
Number of subjects: 54

Group type: COMPARATOR
Intervention: General measures
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Statin
Number of subjects: 54

Group type: COMPARATOR
Intervention: Fenofibrate and control groups (baseline CRP >or=3 mg/dL)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Fenofibrate and control groups (body weight changes)
Number of subjects: 54
Study: 12454833

Group type: EXPERIMENTAL
Intervention: Hypnotherapy (HT)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Supportive therapy
Number of subjects: 126

Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 126
Study: 10511061

Group type: EXPERIMENTAL
Intervention: DX-9065a (0.625 to 30 mg, intravenously administered)
Number of subjects: 0
Study: 7654164

Group type: EXPERIMENTAL
Intervention: Combination of trust and explanation
Number of subjects: 3563

Group type: EXPERIMENTAL
Intervention: Trust only
Number of subjects: 3563

Group type: EXPERIMENTAL
Intervention: Explanation only
Number of subjects: 3563

Group type: COMPARATOR
Intervention: Neither trust nor explanation
Number of subjects: 3563
Study: 2023202

Group type: EXPERIMENTAL
Intervention: Hypnotherapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Physical therapy
Number of subjects: 40
Study: 7195414

Group type: EXPERIMENTAL
Intervention: Nalidixic acid (1 g four times a day) for 14 days
Number of subjects: 81

Group type: COMPARATOR
Intervention: Cephalexin (500 mg four times a day) for 14 days
Number of subjects: 81

Group type: COMPARATOR
Intervention: Cephalexin (500 mg four times a day) for 3 days
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Nalidixic acid (1 g four times a day) for 3 days
Number of subjects: 81
Study: 30782673

Group type: EXPERIMENTAL
Intervention: Wedge‐shaped excision and modified buried vertical mattress suture (WE‐MBVMS)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Buried intradermal suture (BIS)
Number of subjects: 78
Study: 28592063

Group type: EXPERIMENTAL
Intervention: Cisatracurium (0.15 mg/kg) with end-tidal sevoflurane concentration at 2.5%
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Cisatracurium (0.15 mg/kg) with end-tidal sevoflurane concentration at 3.0%
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Cisatracurium (0.15 mg/kg) with end-tidal sevoflurane concentration at 3.5%
Number of subjects: 45
Study: 25379637

Group type: EXPERIMENTAL
Intervention: Selenium (Se) supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22505570

Group type: EXPERIMENTAL
Intervention: Lifestyle + Stress
Number of subjects: 44

Group type: COMPARATOR
Intervention: Lifestyle Alone
Number of subjects: 44
Study: 22105407

Group type: EXPERIMENTAL
Intervention: Driving simulator performance in AD subjects (CDR 0.5 and CDR 1)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Driving simulator performance in cognitively normal elderly controls
Number of subjects: 80
Study: 19015870

Group type: EXPERIMENTAL
Intervention: Leucine
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: BCAAs
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Glutamine
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 17987229

Group type: EXPERIMENTAL
Intervention: DTPa-HBV-IPV/Hib
Number of subjects: 150

Group type: COMPARATOR
Intervention: DTPa-IPV/Hib + HBV
Number of subjects: 150
Study: 15064595

Group type: EXPERIMENTAL
Intervention: Open-loop feedback plus reinforcement intervention
Number of subjects: 18

Group type: COMPARATOR
Intervention: No feedback, no reinforcement control
Number of subjects: 18
Study: 11465619

Group type: EXPERIMENTAL
Intervention: Propofol (target concentration, 1.5 microg/ml)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Alfentanil (12.5 microg/kg intravenous followed by 25 microg.kg(‐1).h(‐1))
Number of subjects: 8
Study: 10223218

Group type: EXPERIMENTAL
Intervention: Sero Strip HIV 1/2 rapid test
Number of subjects: 200
Study: 7604347

Group type: COMPARATOR
Intervention: Saline injection alone
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Chemonucleolysis alone
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Laminectomy for failed intradiscal injection
Number of subjects: 39
Study: 2196144

Group type: EXPERIMENTAL
Intervention: Quinapril (20 mg) administered twice daily for 4 weeks
Number of subjects: 10
Study: 517713

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate 0.6 mg and Neostigmine 2.5 mg i.v.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate 0.6 mg and Neostigmine 5 mg i.v.
Number of subjects: 20
Study: 31218649

Group type: EXPERIMENTAL
Intervention: Bemiparin
Number of subjects: 89
Study: 30325613

Group type: EXPERIMENTAL
Intervention: Artificial urethral sphincter (AUS) implant 'BR - SL - AS - 904'
Number of subjects: 15
Study: 27387696

Group type: EXPERIMENTAL
Intervention: Very Low-Calorie Diet (VLCD) for 2 weeks
Number of subjects: 15

Group type: COMPARATOR
Intervention: Normal Diet for 2 weeks
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Both groups postoperatively (2 weeks and 1 year)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: VLCD
Number of subjects: 15
Study: 25276755

Group type: EXPERIMENTAL
Intervention: Triggers modifying educational intervention (5 weeks, nurse-led)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 60
Study: 22820475

Group type: COMPARATOR
Intervention: No DE Signs (NDES)
Number of subjects: 226
Study: 20233182

Group type: EXPERIMENTAL
Intervention: S‐(+)‐MA 0.25 mg kg(‐1)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: R‐(‐)‐MA 0.25 mg kg(‐1)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 18565951

Group type: EXPERIMENTAL
Intervention: Activated protein C (APC) 24 microg/kg/h for 96 h
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 15939857

Group type: EXPERIMENTAL
Intervention: Children wishing to be thinner at age 8 years
Number of subjects: 435

Group type: COMPARATOR
Intervention: Children satisfied with their size
Number of subjects: 435

Group type: COMPARATOR
Intervention: Children wishing to look heavier
Number of subjects: 435
Study: 14683659

Group type: EXPERIMENTAL
Intervention: Abacavir-lamivudine-tenofovir combination treatment
Number of subjects: 8
Study: 10383524

Group type: EXPERIMENTAL
Intervention: Ibuprofen 1200 mg/day for 10 days
Number of subjects: 1246

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1246
Study: 8522064

Group type: EXPERIMENTAL
Intervention: African-American race
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: Baseline resting systolic blood pressure
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: Pack-years smoking
Number of subjects: 453
Study: 1497770

Group type: EXPERIMENTAL
Intervention: Single-dose cefuroxim (Zinacef)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Three-shot, 24-hour regimen of cefuroxim (Zinacef)
Number of subjects: 106
Study: 6836645

Group type: EXPERIMENTAL
Intervention: Nimodipine infusion (1 microgram kg-1 min-1)
Number of subjects: 16
Study: 2859782

Group type: EXPERIMENTAL
Intervention: Once-daily treatment (n = 97)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Twice-daily treatment (n = 47)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Placebo twice daily (n = 48)
Number of subjects: 192
Study: 30051198

Group type: EXPERIMENTAL
Intervention: Pasireotide-LAR (40 mg/4 weeks)
Number of subjects: 35
Study: 27966503

Group type: EXPERIMENTAL
Intervention: Toothpaste containing 5% potassium nitrate
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Toothpaste containing 5% CSPS (NovaMin)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Toothpaste containing 10% strontium chloride
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Herbal formulation toothpaste
Number of subjects: 160
Study: 24730399

Group type: EXPERIMENTAL
Intervention: Topical tetracaine hydrochloride 1%
Number of subjects: 116

Group type: COMPARATOR
Intervention: Saline eye drops
Number of subjects: 116
Study: 22467148

Group type: EXPERIMENTAL
Intervention: PlasmaJet (PJ)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Helica thermal coagulator (HTC)
Number of subjects: 15
Study: 20124059

Group type: EXPERIMENTAL
Intervention: Minimally invasive approach
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard approach
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study: 18582370

Group type: EXPERIMENTAL
Intervention: Standard treatment plus acupuncture
Number of subjects: 386

Group type: COMPARATOR
Intervention: Standard treatment plus specific stabilising exercises
Number of subjects: 386

Group type: COMPARATOR
Intervention: Standard treatment alone
Number of subjects: 386
Study: 16042730

Group type: EXPERIMENTAL
Intervention: Novel midstream urine-collection device (UCD)
Number of subjects: 2823
Study: 12564745

Group type: EXPERIMENTAL
Intervention: Fast-melting tablet
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Effervescent tablet
Number of subjects: 30

Group type: COMPARATOR
Intervention: Soft gelatin preparation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Powder-filled hard shell preparation
Number of subjects: 30
Study: 11002954

Group type: EXPERIMENTAL
Intervention: Oral misoprostol 400 microg
Number of subjects: 401

Group type: COMPARATOR
Intervention: Intramuscular oxytocin 10 IU
Number of subjects: 401
Study: 9242092

Group type: EXPERIMENTAL
Intervention: Subepithelial connective tissue grafts (SCTG)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Guided tissue regeneration (GTR)
Number of subjects: 36
Study: 1346558

Group type: EXPERIMENTAL
Intervention: Pyridostigmine (30 mg 3 times daily)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Pyridostigmine
Number of subjects: 8
Study: 6383990

Group type: EXPERIMENTAL
Intervention: Flunarizine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nimodipine
Number of subjects: 0
Study: 30577902

Group type: EXPERIMENTAL
Intervention: Methadone treatment in jail-based program
Number of subjects: 520

Group type: COMPARATOR
Intervention: Methadone treatment in community programs
Number of subjects: 520
Study: 30069587

Group type: EXPERIMENTAL
Intervention: Quetiapine XR 300 mg/day
Number of subjects: 431

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 431
Study: 26822428

Group type: COMPARATOR
Intervention: Saline injection (control phase)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blood transfusion
Number of subjects: 0
Study: 25164906

Group type: EXPERIMENTAL
Intervention: Active tVNS (200 μs, 30 Hz; n = 34)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Sham stimulation (n = 14)
Number of subjects: 48
Study: 21960289

Group type: EXPERIMENTAL
Intervention: Specific IgE (sIgE)
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Skin prick test (SPT)
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Total IgE concentration
Number of subjects: 353
Study: 18304540

Group type: EXPERIMENTAL
Intervention: TCM-199
Number of subjects: 13

Group type: COMPARATOR
Intervention: HTF
Number of subjects: 13
Study: 16914240

Group type: EXPERIMENTAL
Intervention: GLURP(85‐213) with Aluminum Hydroxide (Alum)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: GLURP(85‐213) with Montanide ISA 720 (ISA)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: GLURP(85‐213) (10, 30, or 100 microg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control (no specific control group mentioned)
Number of subjects: 36